EVER Pharma is pleased to announce EU-wide marketing authorization of Cabazitaxel for the treatment of adult patients with metastatic prostate cancer1...
Although the Paracelsus Medical Private University (PMU) in Salzburg and EVER Pharma are 40 kilometres apart, their relationship has just moved much...
EVER Pharma Launches Innovative, Patient Friendly Subcutaneous Pump for Parkinson´s Disease
Launched as the D-mine® Pump, this portable micro infusion device recently received European CE approval and is currently being launched in several...
EVER Pharma acquires Amneal Deutschland GmbH and extends its commercial presence in Europe
EVER Pharma Holding Ges.m.b.H (Austria) announced today that it has completed the acquisition of Amneal Deutschland GmbH, a subsidiary of Amneal...
EVER Valinject Launches Dexmedetomidine in Europe: EVER Valinject is pleased to announce the launch of the only dexmedetomidine product in Europe...
Fulvestrant EVER Pharma is the first and only available Fulvestrant in Europe at this time that can be stored at room temperature.
The launch1 of...
EVER PHARMA ACQUIRES PHARMAGEN CZ s.r.o
EVER Pharma has closed an agreement to acquire Pharmagen, a dynamic and rapidly growing pharmaceuticals business in the Czech Republic and Slovakia...
EVER Pharma will invest more than € 100 million over the next 4 years